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Abstract. Despite certain progresses, cancer remains a major cause of death for both humans and 
companion animals, world wide. Chemotherapy is the treatment of choice for many cancer types, but 
it has important limitations because of lack of specificity and numerous side effects, therefore finding 
new cytostatic compounds represent a very active research field. Nowadays, a number of cooper 
complexes have shown an anticancer effect but the pharmacokinetics and mechanisms are not fully 
elucidated yet. In the present study we evaluated the anticancer potential of one new synthesized 
copper complex using a transplantable tumor model on laboratory mice. The tumor model of choice 
was Ehrlich Ascites Carcinoma inoculated intraperitoneally in female Swiss mice. The investigation 
was focused not only on antiproliferative parameters as body weight gain, volume and cytological 
characteristics of ascitic fluid, tumor cell concentration and viability but also on the assessment of side 
effect of tumor growth on general health status. The cooper complex showed an acceptable degree of 
toxicity in preliminary studies. It was responsible for an inhibition up to 80% of body weight gain, and 
prevents the accumulation of the ascitic fluid up to ten fold. The tumor cell concentration was 
consequently decreased by 18-fold, but the cooper complex did not seem to influence the cell viability. 
The hematological parameters and peritoneal cytology revealed also significant changes in response to 
therapy. The new synthesized cooper complex showed promising results; it was able to prevent the 
tumor growth and consequently it seems to improve the body health status. This represents a 
promising starting point for further studies dedicated to create new anticancer molecules. .   
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INTRODUCTION 
 
The synthesis and the chemical investigation of metallodrugs are of significant 
importance because their medicinal application. These applications include use in cancer 
therapy; copper (II) complexes being in focus for decades. The interest for copper complexes is 
justified because they have biologically accessible redox potentials and a significant affinity for 
the nuclear bases (Beckford et al, 2012). The concentration of copper levels are tightly 
regulated, although elevated copper levels are found in many cancer types. Copper seems to 
play a critical role in angiogenesis, which is a critical event in tumor biology (Buac, et al. 2012).  
The cellular targets are not fully elucidated yet, but DNA molecule represents the most 
likely action site (Garcia-Gimenez et al, 2013). Despite numerous studies, the metal containing 
drugs are relatively rare, a platinum containing compound, cisplatin is one of the most effective 
antitumor drug. owever, cisplatin therapy is associated with severe side effects, which limit the 
clinical use (Lopez et al, 2013). Therefore, finding new potential metal based anticancer drugs 
to reduce toxicity is a very active research domain world wide (Zuo, et al, 2012).  
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MATERIALS AND METHODS 
 
Synthesis of cooper complex: The synthesis occurs in the Department of Inorganic 
Chemistry, the molecule has the formula Cu(L)2(py)2(H2O), in which the ligand (HL) is (N-(5-
(4-metilphenyl)-[1,3,4]-tiadiazol-2-il)-benzene sulfonamide). Briefly, the synthesis occurs in 
several steps. A solution of CuSO4· 5H2O (4mmols) in 20 ml of pyridine : H2O [v : v = 1 : 1] 
was added dropwise, under continuous stirring to a solution of HL ligand (1 mmol) dissolved in 
25 ml pyridine : H2O [v: v = 2 : 3]. The resulting solution was stirred at room temperature for 
one hour and left to stand at room temperature. After two months by the slow evaporation of the 
solvent, green-blue crystals suitable for X-ray diffraction were obtained. The crystals were 
purified by filtration, washing and drying several times, until they kept a constant mass.  
The injectable form was obtained by dissolving the copper complex (CuL2) crystals in a 
mixture of glycerol formal and 1,2- propanediol (Sigma-Aldrich) in rapport 2:3 (adapted 
accordingly the patent no. A01251/30.11.2010). The final concentration of CuL2 was 100mg/ml. 
Before injection, the mixture was further diluted in sodium chloride 0.9% sterile solution, while 
the control groups were injected with excipient dissolved in sodium chloride only.  
The animals were caged in groups of 8 per cage, at controlled temperature of 21-22ºC, 
humidity (40-60%) and reversed 12/12h light/dark cycle (light off at 10 a.m.). Standard lab 
chow, provided by National Institute for Research and Development “Cantacuzino” Bucharest 
(Batch no. 2 / 26.03.2010), and water were freely available. The animal tests and experiments 
were allowed by the Bioethical Board of the Faculty of Veterinary Medicine Cluj-Napoca. 
The experiment was carried out on 24 white Swiss female mice, 35.65 ±0.54 g body 
weight. The animals were divided in six equal experimental groups. The first group was the 
Control receiving placebo therapy only and no tumor cells. The other two groups were 
inoculated with Ehrlich Ascitic Carcinoma (EAC); EAC groups received 10
6
 ascitic 
cells/animal intra peritoneal, in the day 0, and the experiment spanned for 14 days.  The 
second group received in addition to EAC a placebo therapy similar to those described for 
control, while the third group benefit from CuL2 treatment, i.p., prepared as described above, 
in the day 1 and 6 - 15 mg./kg bw. In the end, the blood was harvested from the retro orbitary 
sinus under deep narcosis, latter the euthanasia was made by prolonged narcosis. Total 
amount of ascitic fluid was measured, and viable tumor cell concentration was counted in a 
Burker camera (liquid diluted 1:100). Cell viability was assessed by tripan blue staining. 
Blood hematology was investigated with Abacus Junior Vet, automatic analyzer 
Diatron Messtechnik, Budapest, Hungary. 
Statistics - the data were expressed as the mean and standard error of the mean (SEM). 
T Student multiple range test was used to assess the differences between the two groups when 
appreciate the variation of ascitic fluid and cell concentration. Additionally one-way analysis 
of variance ANOVA, followed by post hoc Dunnett’s range test procedure was done for pair-
wise comparisons among the hematological parameters while two-way ANOVA followed by 
Bonferroni post test was the choice for variation of the body weight. 
Statistical significance was at p<0.05 (95% confidence interval). Statistical values and 
figures were obtained using GraphPad Prism version 5.0 for Windows, GraphPad Software, 
San Diego California USA. 
 
RESULTS AND DISCUSSIONS 
 
Expectedly, the development of EAC induced anemia in tumor bearing mice (Tab.1). 
The therapy seems to provide no protective effect; the values were very similar those 
136 
 
untreated. The anemia was responsible for increased anysocytosis but the RBC indices 
remained within normal range (Tab.2). 
Tabel 1 
 
 
The influence of copper complex therapy of EAC inoculated mice on the values  
of the red blood cells (RBCs), hemoglobin (HGB) and hematocrit (HCT) (mean ± S.E.M) 
 
 RBC 10
12
/l HGB g/l HCT % 
Control 8.00±0.47 128.83±7.95 38.58±1.98 
EAC 5.39±0.53 87.8±9.56 26.79±2.73 
EAC + Cu(L)2 5.09±0.55 82.8±9.14 26.75±2.47 
EAC – Ehrlich ascites carcinoma inoculated group, EAC + Cu(L)2 - Ehrlich ascites carcinoma inoculated group 
treated with copper complex  Normal values: RBC 6.5-10.1 10
6
/µl, Hb 101-161 g/l, Ht 22.8-48.0 % (Jain, 1993) 
 
Tabel 2 
 
The influence of copper complex therapy of EAC inoculated mice on the values of mean  
corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin 
concentration (MCHC) and red blood cells distribution width (RDW) (mean ± S.E.M) 
 
 MCV fl MCH pg MCHC g/l RDWs fl 
Control 48.33±0.49 16.08±0.19 332.00±5.07 17.08±0.16 
EAC 49.8±0.19 16.23±0.59 327.8±6.11 36.1±0.83 
EAC + Cu(L)2 53±1.30 16.28±0.33 307.6±7.50 39.06±2.68 
EAC – Ehrlich ascites carcinoma inoculated group, EAC + Cu(L)2 - Ehrlich ascites carcinoma inoculated group 
treated with copper complex  Normal values: MCV 42.3-55.9 fl MCH 13.7-18.1 pg MCHC 29.5-35.1 g/dl (Jain, 1993) 
 
Tabel 3 
 
The influence of copper complex therapy of EAC inoculated mice on the values of total platelet  
count (PLT), platelet hematocrit (PCT), mean platelet volume (MPV), platelet distribution width 
(PDW) (mean ± S.E.M.) 
 
 PLT 10
3
cells/µl PCT % MPV fl PDWs fl 
Control 558.00±35.53 0.39±0.03 7.01±0.08 7.4±0.23 
EAC 1309.8±222.35 0.882±0.16 6.66±0.21 6.94±0.40 
EAC + Cu(L)2 696.6±121.88* 0.476±0.08 6.72±0.12 6.9±0.21 
EAC – Ehrlich ascites carcinoma inoculated group, EAC + Cu(L)2  
Ehrlich ascites carcinoma inoculated group treated with copper complex , *= p<0.05 as compared to EAC group,  
Normal values: PLT 780-1540 10
3
cells/µl (Jain, 1993) 
 
Tabel 4 
The influence of copper complex therapy of EAC inoculated mice  
on the WBC count and differential count (mean ± S.E.M.) 
 
 WBC 10
9
/l LYM 10
9
/l MID 10
9
/l GRA 10
9
/l 
Control   6.85±0.74 5.08±0.62 0.18±0.02   1.59±0.17 
EAC 71.94±6.29 13.19±2.15 6.74±1.70 51.99±5.30 
EAC + Cu(L)2 27.27±6.54** 5.88±1.14* 1.89±0.74* 19.48±5.18** 
EAC – Ehrlich ascites carcinoma inoculated group, EAC + Cu(L)2  
Ehrlich ascites carcinoma inoculated group treated with copper complex   
*= p<0.05 as compared to EAC group, **= p<0.01 as compared to EAC group 
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Normal values: WBC 2.61-10.05 10
3
cells/µl, N 0.4-2.0 10
3
cells/µl, L 1.27-8.44 10
9
/l,  
M 0-0.29 10
3
cells/µl, E 0-0.17 10
3
cells/µl, B 0-0.02 10
3
cells/µl (Jain, 1993) 
 
The EAC inoculation was associated with significant systemic inflammatory 
syndrome reflected hematological by leukocytosis and increased platelets count.  
The granulocytes were in a very high number (neutrophilia), and middle cells were 
also increased. The copper complex therapy reduces the platelets total count and prevents the 
leukocytosis throughout down regulation of granulocytes synthesis. 
The EAC development was responsible for body weight gain, and remarkably, copper 
complex therapy provided a strong protective effect, the animals subject to therapy maintain 
the body mass almost unchanged during entire experiment long (Fig 1.). 
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Fig. 1 The influence of copper complex therapy of EAC inoculated mice on the body weight gain 
(mean ± S.E.M). 
 
EAC – Ehrlich ascites carcinoma inoculated group, EAC + Cu(L)2  
- Ehrlich ascites carcinoma inoculated group treated with copper complex ,  
*= p<0.05 as compared to EAC group, **= p<0.01 as compared to EAC group 
 
The ascitic volume followed the trend of the body weight variation, therefore the cooper 
complex treated group shown very few amount of ascitic fluid (Fig 2a). 
The antiproliferative effect of copper complex was obvious also in the cellular concentration 
in the ascitic fluid (Fig.2b), but it has no influence on viable cells concentration (Fig.3c). The 
antitumor effects of copper complexes are intricate and not fully understood. Many copper 
complexes do not even penetrate the cell membrane and they require conjugation with specific 
peptides (Kanemaru et al. 2011). The most widely accepted target of copper complexes is 
genetic material, in support of this hypothesis; well-documented studies proved that the copper 
complexes are able to bind the DNA molecule (Beckford, et al. 2012). Furthermore, ternary 
copper complexes can interact with the DNA molecule and they induce the DNA cleavage in 
presence of UV light, by a photo-redox pathway with generation of hydroxyl radicals (Garcia-
Gimenez et al. 2013). Other studies showed that neutral and cationic copper 
bis(thiosemicarbazone) complexes inhibit DNA synthesis (Palanimuthu, et al. 2013).  
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The interaction with the DNA molecule leads to an antiproliferative effect, which was 
already proved on model on human cancer cells in vitro (Caco-2 cells) (Garcia-Gimenez et al. 
2013), and in nude mice xenografts (HCT116 cells) (Palanimuthu, et al. 2013). 
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Fig. 2 The influence of copper complex therapy of EAC inoculated mice on the variation of a) the 
volume of the ascitic fluid  (ml), b) the viable cellular concentration within ascitic fluid, (10
6
/ml), c) 
the percentage of non viable cells (%)(mean ± S.E.M.) 
EAC – Ehrlich ascites carcinoma inoculated group, EAC + Cu(L)2 - Ehrlich ascites carcinoma 
inoculated group treated with copper complex ;  ***= p<0.001 as compared to EAC group 
 
However, the anti-mitotic mechanism is not the only one proposed for the copper 
complexes anticancer activity. Chatterjee et al. 2009, proved that copper chelate modulate the 
regulatory cytokine production pattern of tumor associated macrophages, it alter the 
immunosuppressive phenotype of tumor associated macrophages by reprogramming its 
proinflammatory against immunosuppressive pattern, by elevating the production of IL 12 
and down regulating the synthesis of  IL 10 and TGF β. Furthermore, Cu2+ and several copper 
complexes were proved to inhibit the NF-kB pathway (Kanemaru et al. 2011).  
On the other hand, several studies showed that some copper complexes can trigger the 
proteasome inhibition (Zhai, et al. 2010) and apoptosis in human breast (MCF-7) and prostate 
cancer cells (PC-3) (Zuo, et al. 2012). Copper complexes seem to induce a global apoptotic 
mechanism. Cu complex may interact with mitochondria impairing the energetic metabolism 
of the cell, the nucleus resulting in DNA fragmentation, and additionally they generate 
reactive oxygen species (Lopez, et al. 2013). Other studies consider the DNA cleavage as a 
consequence of oxidative stress (Zhensheng, et al., 2012).  The toxicity of copper complexes 
seems to be lower than classic cancer therapy, additionally copper –doxorubicine complex 
preserved the anticancer activity or doxorubicine reduced toxicity and allowed a multi dose 
therapeutic protocol on experimental models (Kheirolomoom, et al. 2010).  
 
CONCLUSIONS 
 
In conclusion, in preliminary study, the administration of copper complex has a significant 
antiproliferative effect on mouse transplantable tumor model; the therapy prevents the body 
weight gain, reduces the volume of the ascitic fluid and reduces the tumor cell concentration. In 
our point of view, those findings justify further pharmacological and chemical studies.  
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